 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Oct 16, 2010 |
| Title |
Expression data from CD133+ and CD133- glioma cells |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Given the very substantial heterogeneity of most human cancers, it is likely that most cancer therapeutics will be active in only a small fraction of any population of patients. As such, the development of new therapeutics, coupled with methods to match a therapy with the individual patient, will be critical to achieving significant gains in disease outcome. One such opportunity is the use of expression signatures to identify key oncogenic phenotypes that can serve not only as biomarkers but also as a means of identifying therapeutic compounds that might specifically target these phenotypes. Given the potential importance of targeting tumors exhibiting a stem-like phenotype, we have developed an expression signature that reflects common biological aspects of various stem-like characteristics. The Consensus Stemness Ranking (CSR) signature is upregulated in cancer stem cell enriched samples, at advanced tumor stages and is associated with poor prognosis in multiple cancer types. Using two independent computational approaches we utilized the CSR signature to identify clinically useful compounds that could target the CSR phenotype. In vitro assays confirmed selectivity of several predicted compounds including topoisomerase inhibitors and resveratrol towards breast cancer cell lines that exhibit a high-CSR phenotype. Importantly, the CSR signature could predict clinical response of breast cancer patients to a neoadjuvant regimen that included a CSR-specific agent. Collectively, these results suggest therapeutic opportunities to target the CSR phenotype in a relevant cohort of cancer patients.
|
| |
|
| Overall design |
CD133+ and CD133- cells were separated from two glioma xenograft tumors. Both CD133+ and CD133- glioma cells were cultured in serum-free media for 48 hours in the presence of absence of laminin.
|
| |
|
| Contributor(s) |
Shats I, Nevins JR |
| Citation(s) |
21169407 |
| Submission date |
Oct 15, 2010 |
| Last update date |
Dec 06, 2018 |
| Contact name |
Igor Shats |
| E-mail(s) |
is37@duke.edu
|
| Organization name |
Duke University
|
| Street address |
101 Science Drive
|
| City |
Durham |
| State/province |
NC |
| ZIP/Postal code |
27710 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL571 |
[HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array |
|
| Samples (8)
|
|
| This SubSeries is part of SuperSeries: |
| GSE24717 |
Using a Stem Cell-Based Signature to Guide Therapeutic Selection in Cancer |
|
| Relations |
| BioProject |
PRJNA133603 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE24716_RAW.tar |
15.4 Mb |
(http)(custom) |
TAR (of CEL) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...